Enlaza Therapeutics has raised $100m in a Series A financing round headed by the Life Sciences group of JP Morgan Asset Management’s private capital division.
The funding round also saw contributions from a mix of existing and new investors, including Frazier Life Sciences, Lightspeed Venture Partners, Avalon Ventures, Samsara BioCapital and Amgen Ventures.
The funds will be channelled towards the development of Enlaza’s covalent protein technologies and will propel its wholly owned pipeline programmes towards clinical trials.
JP Morgan private capital life sciences group chief investment officer Stephen Squinto has joined the board of directors of Enlaza.
War-Lock, the company’s covalent biologic platform, produces highly specific therapeutic warheads which covalently attach to drug targets. This may lead to improved efficacy and reduced toxicities by minimising peripheral exposure.
The War-Lock platform is versatile, with the potential for wide-ranging applications including the production of therapeutic candidates exhibiting excellent drug-like properties.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
The platform’s protein drugs can be tailored with varied payloads, ensuring targeted delivery to specific tissues with high precision.
Enlaza also shared promising preclinical data for its oncology drug candidates. The data underscore the covalent mechanism of action, demonstrating efficient tumour penetration, rapid systemic clearance, high tumour retention and minimal off-target liabilities.
Enlaza Therapeutics CEO Sergio Duron stated: “We are thrilled to close this financing with a group of new and existing investors that share our vision of creating a novel, differentiated class of protein therapeutics in oncology and other therapeutic areas.
“This support will enable continued expansion of our covalent protein drug platform, [the] establishment of a diversified pipeline that demonstrates the broad potential of this approach, and advancement of our lead assets toward clinical development.”
